The Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information on brain tumor chemotherapy research. This book represents the most complete, single-volume resource available for information on the subject of brain tumor chemotherapy. Including a multidisciplinary approach, this volume combines recent advances in tumor therapy with molecular biology, molecular therapeutics, immunobiology, and immunotherapy approaches in one compilation. Chapters new to this volume include cutting-edge research on the molecular underpinnings of brain tumors such as glioblastoma and other gliomas, and the targeted molecular therapies to consider for treatment.
• Offers an up-to-date review of brain tumor chemotherapy
• Includes separate chapters on all major brain tumor types
• Includes an overview of molecular biology and developmental molecular therapeutics
• Features new materials on molecular approaches to brain metastases, methylation analysis, liquid biopsy, cancer neuroscience, and RNA sequencing
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xix 8. About the editor - p. xxv 9. Preface - p. xxvii 10. 1: Pharmacology & Clinical Application - p. S1 11. Chapter 1. Pathology of primary and metastatic brain tumors - p. 3 12. Chapter 2. Clinical pharmacology of brain tumor chemotherapy - p. 15 13. Chapter 3. Anti-seizure drugs and cancer therapies: potential interactions and impact on treatment - p. 45 14. Chapter 4. Preclinical models for chemotherapy development - p. 65 15. Chapter 5. Genomics and proteomics in neurooncology - p. 79 16. Chapter 6. Methylation analysis and application to brain tumors - p. 91 17. Chapter 7. Next-generation sequencing: overview and application to systemic cancer and brain tumors - p. 107 18. Chapter 8. Liquid biopsy for neuro-oncology: a non-invasive window into tumor biology - p. 139 19. Chapter 9. Overview of RNA-sequencing and applications to neuro-oncology - p. 153 20. Chapter 10. Chemotherapy resistance - p. 169 21. Chapter 11. Clinical trial design and implementation in neuro-oncology - p. 191 22. Chapter 12. Neuro-Oncology and the blood–brain barrier - p. 203 23. 2: Innovative Chemotherapy Delivery - p. S219 24. Chapter 13. Intraarterial chemotherapy of brain tumors - p. 221 25. Chapter 14. Blood Brain Barrier disruption chemotherapy - p. 237 26. Chapter 15. Interstitial chemotherapy and polymer drug delivery - p. 249 27. Chapter 16. Intratumoral chemotherapy and convection-enhanced delivery - p. 265 28. Chapter 17. Marrow-ablative high dose chemotherapy with autologous hematopoietic progenitor cell rescue in pediatric brain tumors - p. 285 29. Chapter 18. Cerebrospinal fluid dissemination of primary brain tumors - p. 301 30. Chapter 19. Gene and viral therapy approaches for brain tumors - p. 323 31. Chapter 20. Nanoparticles for CNS cancer therapy - p. 345 32. 3: Molecular Biology & Molecular Therapeutics - p. S375 33. Chapter 21. An overview of molecular genetics of brain tumors - p. 377 34. Chapter 22. Cell cycle regulation - p. 387 35. Chapter 23. Targeting cell cycle proteins in brain cancer - p. 397 36. Chapter 24. Cell death pathways and chemotherapy in brain tumors - p. 425 37. Chapter 25. Growth factor signaling pathways and targeted therapy - p. 445 38. Chapter 26. Targeting the RAS/RAF/MEK/ERK signaling pathway in gliomas - p. 467 39. Chapter 27. PI3-kinase, Akt, mTOR, and treatment - p. 481 40. Chapter 28. Scatter factor/hepatocyte growth factor and c-Met in glioblastoma - p. 493 41. Chapter 29. Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors - p. 501 42. Chapter 30. Sonic Hedgehog signaling pathway: overview and treatment considerations in brain tumors - p. 515 43. Chapter 31. Isocitrate dehydrogenase mutations in brain tumors: overview and approache to treatment - p. 527 44. Chapter 32. Angiogenesis and angiogenesis inhibitors in brain tumors - p. 543 45. Chapter 33. Bevacizumab and brain tumors - p. 557 46. Chapter 34. Histone deacetylase inhibitors as antineoplastic agents in neuro-oncology - p. 569 47. Chapter 35. Cancer neuroscience and brain tumors - p. 591 48. 4: Chemo Specific Tumors – Adults - p. S601 49. Chapter 36. Chemo of high-grade astrocytomas—traditional - p. 603 50. Chapter 37. Chemotherapy of high-grade astrocytomas: temozolomide - p. 617 51. Chapter 38. Molecular therapy of glioblastoma, IDH-wildtype - p. 631 52. Chapter 39. Chemotherapy of low-grade astrocytomas - p. 649 53. Chapter 40. Chemotherapy of oligodendrogliomas - p. 663 54. Chapter 41. Chemotherapy for primary central nervous system lymphoma - p. 675 55. Chapter 42. Chemotherapy for medulloblastoma in adults - p. 693 56. Chapter 43. Chemotherapy of adult ependymoma - p. 705 57. Chapter 44. Medical therapies for glioneuronal tumors - p. 709 58. Chapter 45. Medical therapy of schwannomas - p. 729 59. Chapter 46. Chemotherapy of pineal parenchymal tumors - p. 739 60. Chapter 47. Chemotherapy of meningiomas - p. 749 61. Chapter 48. Traditional chemotherapy approaches for metastatic brain tumors - p. 769 62. Chapter 49. Molecular approaches to brain metastasis - p. 785 63. 5: Chemo Specific Tumors – Pediatrics - p. S803 64. Chapter 50. Chemotherapy of pediatric low-grade gliomas - p. 805 65. Chapter 51. Chemotherapy of pediatric high-grade gliomas - p. 821 66. Chapter 52. Chemotherapy for medulloblastoma—childhood - p. 839 67. Chapter 53. Chemotherapy of brainstem gliomas - p. 859 68. Chapter 54. Germ cell tumors - p. 873 69. Chapter 55. Chemotherapy of ependymoma: childhood - p. 889 70. Chapter 56. Chemotherapy for central nervous system atypical teratoid/rhabdoid tumor - p. 903 71. Chapter 57. Pediatric choroid plexus tumors: current management and future directions - p. 915 72. 6: Immunotherapy Of Bt’s - p. S933 73. Chapter 58. Glioblastoma and the immune milieu: overview and focus on immune checkpoint blockade - p. 935 74. Chapter 59. Checkpoint inhibitor and T-cell-based immunotherapy for brain tumors - p. 951 75. Chapter 60. Overview of dendritic cell vaccines for brain tumors - p. 969 76. Chapter 61. Overview of vaccine strategies against epidermal growth factor receptor in brain tumors - p. 989 77. Chapter 62. Overview of central nervous system vaccines—pediatrics - p. 1009 78. 7: Response Assessment, Quality Of Life, Neuropsychology, And New Frontiers - p. S1017 79. Chapter 63. Issues in response assessment of brain tumor to chemotherapy - p. 1019 80. Chapter 64. Pseudoprogression in neuro-oncology: overview, pathophysiology, and interpretation - p. 1037 81. Chapter 65. Response assessment in neuro-oncology: an update - p. 1059 82. Chapter 66. Quality of life in neuro-oncology - p. 1075 83. Chapter 67. Neuropsychology in patients with cancer - p. 1093 84. Chapter 68. Artificial intelligence applications in neuro-oncology - p. 1125 85. Chapter 69. Ayurveda and ashwagandha: overview of bioactive components and potential applications to gliomas - p. 1139 86. Index - p. 1157
The Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information on brain tumor chemotherapy research. This book represents the most complete, single-volume resource available for information on the subject of brain tumor chemotherapy. Including a multidisciplinary approach, this volume combines recent advances in tumor therapy with molecular biology, molecular therapeutics, immunobiology, and immunotherapy approaches in one compilation. Chapters new to this volume include cutting-edge research on the molecular underpinnings of brain tumors such as glioblastoma and other gliomas, and the targeted molecular therapies to consider for treatment.
• Offers an up-to-date review of brain tumor chemotherapy
• Includes separate chapters on all major brain tumor types
• Includes an overview of molecular biology and developmental molecular therapeutics
• Features new materials on molecular approaches to brain metastases, methylation analysis, liquid biopsy, cancer neuroscience, and RNA sequencing
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xix 8. About the editor - p. xxv 9. Preface - p. xxvii 10. 1: Pharmacology & Clinical Application - p. S1 11. Chapter 1. Pathology of primary and metastatic brain tumors - p. 3 12. Chapter 2. Clinical pharmacology of brain tumor chemotherapy - p. 15 13. Chapter 3. Anti-seizure drugs and cancer therapies: potential interactions and impact on treatment - p. 45 14. Chapter 4. Preclinical models for chemotherapy development - p. 65 15. Chapter 5. Genomics and proteomics in neurooncology - p. 79 16. Chapter 6. Methylation analysis and application to brain tumors - p. 91 17. Chapter 7. Next-generation sequencing: overview and application to systemic cancer and brain tumors - p. 107 18. Chapter 8. Liquid biopsy for neuro-oncology: a non-invasive window into tumor biology - p. 139 19. Chapter 9. Overview of RNA-sequencing and applications to neuro-oncology - p. 153 20. Chapter 10. Chemotherapy resistance - p. 169 21. Chapter 11. Clinical trial design and implementation in neuro-oncology - p. 191 22. Chapter 12. Neuro-Oncology and the blood–brain barrier - p. 203 23. 2: Innovative Chemotherapy Delivery - p. S219 24. Chapter 13. Intraarterial chemotherapy of brain tumors - p. 221 25. Chapter 14. Blood Brain Barrier disruption chemotherapy - p. 237 26. Chapter 15. Interstitial chemotherapy and polymer drug delivery - p. 249 27. Chapter 16. Intratumoral chemotherapy and convection-enhanced delivery - p. 265 28. Chapter 17. Marrow-ablative high dose chemotherapy with autologous hematopoietic progenitor cell rescue in pediatric brain tumors - p. 285 29. Chapter 18. Cerebrospinal fluid dissemination of primary brain tumors - p. 301 30. Chapter 19. Gene and viral therapy approaches for brain tumors - p. 323 31. Chapter 20. Nanoparticles for CNS cancer therapy - p. 345 32. 3: Molecular Biology & Molecular Therapeutics - p. S375 33. Chapter 21. An overview of molecular genetics of brain tumors - p. 377 34. Chapter 22. Cell cycle regulation - p. 387 35. Chapter 23. Targeting cell cycle proteins in brain cancer - p. 397 36. Chapter 24. Cell death pathways and chemotherapy in brain tumors - p. 425 37. Chapter 25. Growth factor signaling pathways and targeted therapy - p. 445 38. Chapter 26. Targeting the RAS/RAF/MEK/ERK signaling pathway in gliomas - p. 467 39. Chapter 27. PI3-kinase, Akt, mTOR, and treatment - p. 481 40. Chapter 28. Scatter factor/hepatocyte growth factor and c-Met in glioblastoma - p. 493 41. Chapter 29. Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors - p. 501 42. Chapter 30. Sonic Hedgehog signaling pathway: overview and treatment considerations in brain tumors - p. 515 43. Chapter 31. Isocitrate dehydrogenase mutations in brain tumors: overview and approache to treatment - p. 527 44. Chapter 32. Angiogenesis and angiogenesis inhibitors in brain tumors - p. 543 45. Chapter 33. Bevacizumab and brain tumors - p. 557 46. Chapter 34. Histone deacetylase inhibitors as antineoplastic agents in neuro-oncology - p. 569 47. Chapter 35. Cancer neuroscience and brain tumors - p. 591 48. 4: Chemo Specific Tumors – Adults - p. S601 49. Chapter 36. Chemo of high-grade astrocytomas—traditional - p. 603 50. Chapter 37. Chemotherapy of high-grade astrocytomas: temozolomide - p. 617 51. Chapter 38. Molecular therapy of glioblastoma, IDH-wildtype - p. 631 52. Chapter 39. Chemotherapy of low-grade astrocytomas - p. 649 53. Chapter 40. Chemotherapy of oligodendrogliomas - p. 663 54. Chapter 41. Chemotherapy for primary central nervous system lymphoma - p. 675 55. Chapter 42. Chemotherapy for medulloblastoma in adults - p. 693 56. Chapter 43. Chemotherapy of adult ependymoma - p. 705 57. Chapter 44. Medical therapies for glioneuronal tumors - p. 709 58. Chapter 45. Medical therapy of schwannomas - p. 729 59. Chapter 46. Chemotherapy of pineal parenchymal tumors - p. 739 60. Chapter 47. Chemotherapy of meningiomas - p. 749 61. Chapter 48. Traditional chemotherapy approaches for metastatic brain tumors - p. 769 62. Chapter 49. Molecular approaches to brain metastasis - p. 785 63. 5: Chemo Specific Tumors – Pediatrics - p. S803 64. Chapter 50. Chemotherapy of pediatric low-grade gliomas - p. 805 65. Chapter 51. Chemotherapy of pediatric high-grade gliomas - p. 821 66. Chapter 52. Chemotherapy for medulloblastoma—childhood - p. 839 67. Chapter 53. Chemotherapy of brainstem gliomas - p. 859 68. Chapter 54. Germ cell tumors - p. 873 69. Chapter 55. Chemotherapy of ependymoma: childhood - p. 889 70. Chapter 56. Chemotherapy for central nervous system atypical teratoid/rhabdoid tumor - p. 903 71. Chapter 57. Pediatric choroid plexus tumors: current management and future directions - p. 915 72. 6: Immunotherapy Of Bt’s - p. S933 73. Chapter 58. Glioblastoma and the immune milieu: overview and focus on immune checkpoint blockade - p. 935 74. Chapter 59. Checkpoint inhibitor and T-cell-based immunotherapy for brain tumors - p. 951 75. Chapter 60. Overview of dendritic cell vaccines for brain tumors - p. 969 76. Chapter 61. Overview of vaccine strategies against epidermal growth factor receptor in brain tumors - p. 989 77. Chapter 62. Overview of central nervous system vaccines—pediatrics - p. 1009 78. 7: Response Assessment, Quality Of Life, Neuropsychology, And New Frontiers - p. S1017 79. Chapter 63. Issues in response assessment of brain tumor to chemotherapy - p. 1019 80. Chapter 64. Pseudoprogression in neuro-oncology: overview, pathophysiology, and interpretation - p. 1037 81. Chapter 65. Response assessment in neuro-oncology: an update - p. 1059 82. Chapter 66. Quality of life in neuro-oncology - p. 1075 83. Chapter 67. Neuropsychology in patients with cancer - p. 1093 84. Chapter 68. Artificial intelligence applications in neuro-oncology - p. 1125 85. Chapter 69. Ayurveda and ashwagandha: overview of bioactive components and potential applications to gliomas - p. 1139 86. Index - p. 1157
